Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16095457 | 0.81 | PSEN1 (0.34) | HSD11B1 | |
| SCHEMBL16118390 | 0.74 | — | — | |
| SCHEMBL4852646 | 0.71 | DRD2 (0.32) | CXCR2 | |
| SCHEMBL7700874 | 0.71 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL31263267 | 0.70 | — | — | |
| SCHEMBL31263221 | 0.70 | — | — | |
| SCHEMBL31263058 | 0.69 | — | — | |
| SCHEMBL1448551 | 0.69 | — | — | |
| SCHEMBL3653567 | 0.69 | AKR1C3 (0.32) | — | |
| SCHEMBL25136394 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214566-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-04 | — | — | US | disclosed |
| US-20200399254-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-24 | — | — | US | disclosed |
| US-10800764-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| US-9611259-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399254-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | FLT3, ABL1, FES | HSD11B1 4667/4885CXCR2 812/4885CXCR1 1538/4885 |
| US-10800764-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | FLT3, ABL1, FES | HSD11B1 4667/4885CXCR2 812/4885CXCR1 1538/4885 |
| US-11214566-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | FLT3, ABL1, FES | HSD11B1 4667/4885CXCR2 812/4885CXCR1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.